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The human uterus consists of the inner endometrium, the myometrium, and the outer serosa. Knowledge of the function of the
uterus in health and disease is relevant to reproduction, fertility, embryology, gynaecology, endocrinology, and oncology.
Research performed on uterine biopsies is essential to further the current understanding of human uterine biology. This brief
review explores the value of the uterine biopsy in gynaecological and human fertility research and explores the common
problems encountered when analysing data generated from different types of uterine biopsies, with the aim of improving the
quality, reproducibility, and clinical translatability of future research.
1. Introduction
Reproductive, fertility, embryology, and early developmental
researchers as well as gynaecologists, endocrinologists, and
cancer biologists routinely study the human uterus, as it is
an organ pertinent to all of their lines of investigation. The
uterus is a hormonally responsive organ, and it is the princi-
pal target for many hormones including ovarian sex steroids
[1, 2]. The main discerning feature of the human uterus is
menstruation, which is a unique process, and is limited to
humans and upper-order primates; thus, this particular
aspect of human uterine biology cannot easily be modelled
in common laboratory animal models (e.g., murine or rodent
models) [3]. Therefore, patient-derived uterine biopsies are
invaluable to further our current understanding of human
uterine biology. The human uterus is a “pear”-shaped pelvic
organ with the fundamental purpose of accommodating the
embryo/fetus until delivery. The term “uterus” usually
excludes the fallopian tubes and the cervix; both of which
exist as a continuum of the uterine body. The uterine wall
comprises of three layers (Figure 1): (1) the outer serosa
which contains the perimetrial cover derived from the
embryonic visceral peritoneum; (2) the myometrium con-
taining specialised smooth muscle, stroma, and blood vessels;
and (3) the endometrium, which is a complex inner mucosal
layer that contains the epithelium, stroma, blood vessels, and
leucocytes. The term “uterine biopsy” can therefore represent
a tissue sample containing any one or all of these tissue
layers. However, the myometrium and endometrium are
the two main layers of the human uterine wall that are rou-
tinely biopsied and studied by uterine biologists.
2. Harvesting the Endometrium
The inner lining of the uterus, the endometrium, is easily
accessible through the hollow structure, the cervix, located
at the lower part of the uterus, which opens into the vagina.
The endometrium extends to the internal cervical os and
the upper part of the endocervix (Figure 1). It comprises
two functionally distinct layers, the superficial functionalis,
and the deeper basalis that lies on the underlying myome-
trium (Figure 2) [4, 5].
In premenopausal women, the functionalis is easily
accessible and can be harvested with outpatient and inpatient
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biopsy methods, either using suction (pipelle) curettes
(Figure 3) or scraping with metal curettes. However, the
deeper basalis is not usually accessible in a preserved intact
premenopausal uterus, and with pipelle or even more exten-
sive curette biopsies, the amount of functionalis obtained
depends hugely on the optimal sampling technique and on
the cycle phase. For example, pipelle biopsies obtained at the
time of spontaneous (menstrual phase) or iatrogenic (trau-
matic) bleeding may contain mostly blood without much
endometrial tissue. Some of these problems can be overcome
by adapting special techniques in an intact uterus, such as
resection of the endometrium under direct vision with hyster-
oscopy to obtain a full-thickness endometrial sample contain-
ing basalis. However, this is usually an additional and a more
invasive procedure, which may not be routinely performed,
therefore will require further ethical considerations, necessi-
tating additional time, counselling regarding specific-risks,
and thus resources [6]. The premenopausal basalis can also
be harvested as a wedge biopsy from a hysterectomy specimen,
where a full-thickness endometrial sample can be obtained
containing the functionalis, the basalis, and the underlying
myometrium [7] (Figure 3). It is important to note, however,
that the indication for hysterectomy is usually an underlying
uterine pathology, such as heavy menstrual bleeding, endome-
triosis, or malignancy [8]; therefore, the samples may not be
representative of a normal healthy endometrium. Further-
more, most women undergo hysterectomy for benign condi-
tions when medical therapy fails, thus will be routinely still
on hormonal treatment, such as the Mirena intrauterine
device or gonadotropin-releasing hormone (GnRH) analogue
treatments. Such exogenous hormones will alter endometrial
phenotype and function, and therefore, a wash out period after
hormone exposure is indicated when examining the normal
endometrium (of at least 3 months after being on any hor-
monal therapy) to avoid exogenous hormonal influence. Some
authors have harvested placental bed biopsies at the time of
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Figure 1: Human uterus and cervix removed at hysterectomy, with a vertical incision on the anterior aspect, representing macroscopic
uterine anatomy.
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Figure 2: Representative micrograph (4x) of full-thickness human uterine biopsies taken from pre- and postmenopausal women, containing
both endometrium and subendometrial myometrium stained with haematoxylin and eosin.
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delivery of a baby, where decidual tissue with some superficial
myometrial tissue is obtained [9].
Contrastingly, in postmenopausal women and premeno-
pausal women on hormonal preparations that preclude the
influence of cyclical ovarian hormones on the endome-
trium, (e.g. GnRH analogues), there is no endometrial func-
tionalis layer. Therefore, when the endometrium is sampled,
the harvested biopsies will only contain the stem cell-rich
basalis layer of the endometrium [10, 11]. Furthermore,
full-thickness biopsies taken from this thin endometrium in
a hysterectomy sample (and even possibly from a curettage)
invariably contain the underlying myometrium; thus, the
studies examining the expression of endometrial-specific
genes may be affected by the myometrial expression levels
that are included in the whole biopsy. In endometrial cancer
research, it is challenging, and not usually possible, to obtain
a full-thickness uterine biopsy for snap freezing or RNA
studies, as the specimen must be initially preserved whole
for pathologists’ scrutiny and staging purposes [3]. Hence,
curettes or pipelle biopsies are the only available sampling
methods for most studies. Depending on the size and the
nature of the cancer, a superficial endometrial biopsy may
contain a malignant or benign endometrium, or a combina-
tion. The actual proportion of cancer cells included in a
whole frozen or freshly collected tissue biopsy may affect
the data obtained but is not easy to determine. Haematoxy-
lin and eosin (H&E) staining and morphological assessment
of the frozen tissue sections may be suitable in some
instances. Furthermore, others have also explored the possi-
bility of examining the uterine fluid that represents the
cytokine or metabolic milieu of the endometrium related
to a particular pathology [12].
There are significant changes in the endometrial cell phe-
notype and function during different phases of the menstrual
cycle [1, 13], including proliferation, decidualisation, and
changes in hormone responsiveness. The cellular composi-
tion also changes significantly across the menstrual cycle.
For example, a sample containing secretory-phase functiona-
lis layer will contain leucocytes accounting for up to 30%
stromal cells due to the massive leucocyte infiltration that
occurs at the end of the cycle [14]. These changes in cellular
proliferation and composition are mainly limited to the
functionalis layer, which is relevant to fertility and premen-
opausal gynaecological conditions, such as heavy menstrual
bleeding [15, 16]. Therefore, fertility researchers focus
mainly on this layer for the obvious reasons, and they often
take biopsies that only contain the functionalis layer from
women who wish to preserve their uterus and thus their
fertility [17, 18]. In contrast, stem cell biologists focus more
on the basalis layer since it has been postulated to harbour
endometrial stem cells [5, 10].
Since the endometrium is the primary target organ for
ovarian hormones, the endometrial biopsy should naturally
be examined in the context of the menstrual cycle phase
and thus with relevance to the distinct ovarian hormonal
influence of that phase [1]. Frequently, cell type-specific gene
expression or protein quantitative studies process whole
endometrial samples without necessarily considering the dif-
fering cell types included in each sample [19–21]; therefore,
cell type-specific changes maybe diluted or masked in the
results obtained by analysing the whole biopsy. Unless nor-
malisation using a specific marker is performed, such as
marking epithelial cells with cytokeratin to assess the propor-
tion of the particular cell type present in the biopsy, the final
results will be prejudiced by the heterogeneity of the cell types
included [11, 22, 23].
The cell-cell interaction between the different cell types of
the endometrium is also important, with evidence suggesting
that cross-talk between the epithelial and stromal cells plays
an important role in hormonal regulation, for example, in
the context of steroid hormone receptor expression [1, 2].
Methods which do not disturb the tissue architecture but
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Figure 3: Image of a human uterus with representative micrographs of (a) full-thickness endometrial biopsy (100x) from a hysterectomy
specimen and (b) pipelle endometrial biopsy (4x), depicting the distinct anatomical areas included in each of them when the human
uterus is sampled with different methods. (1) Luminal epithelium, (2) functionalis, (3) basalis, and (4) myometrium.
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directly assess the gene or protein expression at a cellular
level, such as in situ hybridisation [11], immunohistochemis-
try [21], or immunofluorescence [23], will remove this bias.
Isolating cells directly can also be achieved with antibody-
based fluorescence-activated cell sorting (FACS) [10] or
magnetic bead sorting [23] which will also allow extended
functional studies in the isolated, viable cells employing
either in vitro or in vivo models. Techniques such as laser
capture microdissection [24, 25] can also be employed to
extract a particular cell type from a frozen tissue section. This
method will allow direct comparison and further in-depth
analysis of endometrial epithelial and stromal cells from the
different endometrial compartments. Furthermore, the novel
technique imaging mass cytometry (Fluidigm) has recently
been optimised for the first time in the endometrium, broad-
ening our ability to study the endometrium in detail [26].
Techniques like this provide a remarkable platform for
highly detailed functional and phenotypic analysis of endo-
metrial tissue, in this case employing metal-labelled antibod-
ies, rather than the fluorochromes that are used in traditional
flow cytometry or in immunofluorescence studies. Therefore,
it allows simultaneous analysis of a greater number of
markers in a single endometrial tissue section. Although cell
type-specific spatial expression of genes or gene products can
be observed with aforementioned methods, the quantifica-
tion still poses a challenge. The use of a variety of semiquan-
titative scoring systems2 and computer-based image analysis
methods [14] has attempted to reduce observer bias; but
none have removed the problem completely. The use of these
new techniques and further studies on optimising the ana-
lytic methods used will continue to increase our understand-
ing of the human endometrial architecture and cell-specific
functions.
In order to avoid common pitfalls, researchers examining
endometrial biopsies should follow the already published,
elaborative, and standard operating procedures that are
available for specific pathologies [7, 27]. These were designed
to harmonise the data generated using human endometrial
samples and to improve the quality, reproducibility, and clin-
ical translatability of the research.
2.1. Solutions for Common Problems with
Endometrial Sampling
2.1.1. Pipelle Endometrial Biopsy/Endometrial Curettings.
The main problems encountered with these biopsies are (1)
the inclusion of insufficient endometrial material and (2)
sampling of endometrial functionalis only, unless in certain
patients (e.g. postmenopausal women or those on particular
hormonal preparations such as gonadotrophin-releasing
hormone analogues/progestogens, which curtail the effects
of dynamic and cyclical ovarian hormones to produce an
endometrial functionalis). To rectify or account for these
issues, careful histological evaluation of the biopsy content
should be undertaken by a trained histopathologist and
reported in the publication accordingly [2, 4, 10, 11, 17].
2.1.2. Harvesting the Endometrium from Hysterectomy
Samples. Studies collecting the endometrium from hysterec-
tomy samples should, from the outset, clarify if they intend
to collect either full-thickness samples (which requires open-
ing of the uterine cavity) or other scraping or suction
methods that would access mostly the endometrial functio-
nalis. When the full-thickness endometrium is collected, the
methodology should include details on the exact location in
the uterine cavity (e.g., fundal, anterior, or posterior wall)
where the biopsy is taken. If the study compared data gener-
ated using samples of the endometrium from women who
have only a basalis layer (e.g., postmenopausal), with the
endometrium of premenopausal women who have a thicker
endometrium with obvious basalis and functionalis regions,
it is essential to clarify the exact layer that is compared to pro-
vide robust and reproducible results [2]. Inclusion of myo-
metrium cells in the whole “endometrial” sample in a full-
thickness sample can affect some data. For example, if myo-
metrial cells have a distinct gene expression pattern that
may erroneously be interpreted as relevant to the endome-
trium. The use of specific techniques such as laser capture
microdissection would allow accurate isolation of a particular
cell type in this instance. If the endometrium is obtained
from the hysterectomy specimen using suction or scraping
without opening the uterus, the precautions mentioned in
Section 2.1.1 above should be followed.
3. Harvesting the Myometrium
Myometrial samples are most commonly harvested during a
caesarean section (CS), as the myometrium is easily accessi-
ble from the uterine incision [28]. The uterine incision at a
routine CS is a transverse incision on the anterior aspect of
the lower uterine segment. The lower segment of the uterus
is typically developed at late gestation and in labour and lies
between the physiological retraction ring and the obstetrical
internal os [29]. It is a thinner, more fibrous part of the myo-
metrium, which is also less active than the rest of the uterine
corpus in a labouring uterus [30, 31]. A myometrial biopsy
can be taken from the upper or the lower edge of the trans-
verse uterine incision [28]. Myometrial functional studies as
well as many molecular biological studies are often per-
formed on these biopsies. However, the results can be
affected by obesity, diabetes, gestation, the presence or
absence of labour, singleton or twin pregnancy, and fibrosis
from previous uterine surgery [32–35]. Furthermore, data
should be interpreted in the context of these biopsies being
obtained from a gravid uterus, which has undergone massive
hypertrophy [36] and has been exposed to the pregnancy
related hormonal milieu [37]. The location of the myome-
trial biopsy may also have implications for data analysis;
for example, a biopsy taken from the upper uterine segment
at a classical CS (where a vertical incision is made into the
upper uterine segment) may have different properties to
the myometrium obtained from a lower uterine segment
[38]; however, in relation to contractility studies, current evi-
dence suggests that there is no significant difference between
myometrial biopsies obtained from upper and lower uterine
segments [39].
The nonpregnant myometrium can be sampled at the
time of gynaecological surgery, typically after hysterectomy
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[40] or at myomectomy. Myomectomy samples may contain
leiomyomatous tissue, but a sample obtained at hysterectomy
can be taken from any part of the uterus, with or without
commonly occurring pathological lesions such as leiomyo-
mata or adenomyomas [16]. Interestingly, published func-
tional studies commonly compare the nonpregnant and
pregnant myometrium, for example assessing the contractil-
ity of muscle fibres, but do not necessarily consider the
impact of comparing muscle fibres derived from different
uterine areas [41, 42]. This may impact the quality of the data
generated, for example, if the non-pregnant myometrial
fibres were obtained from the uterine fundus, whilst pregnant
myometrium was derived from the lower segment of the
uterus [43]. This issue is further complicated by the fact that
no discernible lower segment exists in a nonpregnant uterus;
thus, we propose that attempts should be made to collect
myometrial tissue from the anterior lower uterine body in
nonpregnant uterus and from the upper edge of the trans-
verse CS incision to strive to obtain similar tissue for compar-
ative studies. Finally, since the myometrium contains distinct
myometrial layers [43, 44], the exact layer muscle fibres are
derived from may also confound the results.
4. Conclusion
In summary, uterine biopsies are a valuable source of human
tissue, and studies using these biospecimens have contributed
significantly to our current understanding of pregnancy, fer-
tility, and many gynaecological disorders. When collecting
and processing uterine biopsies for studies and biobanking,
careful consideration is essential of the many pitfalls that
can confound the results obtained from them, and strict
adherence to published standard operative procedures is also
imperative. This will enable researchers to utilise these
important biospecimens to discover diagnostic and thera-
peutic targets for the benefit of millions of women suffering
from obstetric and gynaecological conditions.
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